Therapeutic potential of nitric oxide-modified drugs in colon cancer cells

Molecular Pharmacology

Volumn 82, Issue 4, 2012, Pages 700-710

  Mojic, Marija ^a   Mijatovic, Sanja ^a   Maksimovic Ivanic, Danijela ^a   Miljkovic, Djordje ^a   Stosic Grujicic, Stanislava ^a   Stankovic, Marija ^b   Mangano, Katia ^c   Travali, Salvatore ^c   Donia, Marco ^c   Fagone, Paolo ^c   Zocca, Mai Britt ^d   Al Abed, Yousef ^e   McCubrey, James A ^f   Nicoletti, Ferdinando ^c,d  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Belgrade University   (Serbia)

^c UNIVERSITY OF CATANIA   (Italy)

^d Onconox Aps   (Denmark)

^e East Carolina University ^*  (United States)

^f EAST CAROLINA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; GIT 20 NITRIC OXIDE; NITRIC OXIDE; NITROGEN DERIVATIVE; OXYGEN DERIVATIVE; PEROXYNITRITE; SAQUINAVIR; SAQUINAVIR NITRIC OXIDE; UNCLASSIFIED DRUG; VGX 1027;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INVASION; CELL ADHESION; CELL CULTURE; CELL DESTRUCTION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ACETATES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NITRIC OXIDE; OXAZOLES; SAQUINAVIR;

EID: 84866853268     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.077842     Document Type: Article

References (44)

1. Bernstein WB and Dennis PA (2008) Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS 3:666-675.
2. Bower M, Fox P, Fife K, Gill J, Nelson M, and Gazzard B (1999) Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 13:2105-2111. (Pubitemid 29509588)
3. Calcerrada P, Peluffo G, and Radi R (2011) Nitric oxide-derived oxidants with a focus on peroxynitrite: molecular targets, cellular responses and therapeutic implications. Curr Pharm Des 17:3905-3932.
4. Canducci F, Ceresola ER, Saita D, Al-Abed Y, Garotta G, Clementi M, and Nicoletti F (2011) The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir. Antiviral Res 91:292-295.
5. Chow WA, Jiang C, and GuanM(2009) Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 10:61-71.
6. Coimbra M, Kuijpers SA, van Seters SP, Storm G, and Schiffelers RM (2009) Targeted delivery of anti-inflammatory agents to tumors. Curr Pharm Des 15:1825-1843.
7. Dang DT, Chen F, Kohli M, Rago C, Cummins JM, and Dang LH (2005) Glutathione S-transferase pi1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res 65:9485-9494. (Pubitemid 41508018)
8. Donia M, Maksimovic-Ivanic D, Mijatovic S, Mojic M, Miljkovic D, Timotijevic G, Fagone P, Caponnetto S, Al-Abed Y, McCubrey J, et al. (2011) In vitro and in vivo anticancer action of saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle 10:492-499.
9. Donia M, Mijatovic S, Maksimovic-Ivanic D, Miljkovic D, Mangano K, Tumino S, Biondi A, Basile F, Al-Abed Y, Stosic-Grujicic S, et al. (2009) The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis. Eur J Pharmacol 615:228-233.
10. Fagone P, Mangano K, Coco M, Perciavalle V, Garotta G, Romao CC, and Nicoletti F (2012) Therapeutic potential of carbon monoxide in multiple sclerosis. Clin Exp Immunol 167:179-187.
11. Fenton TR and Gout IT (2011) Functions and regulation of the 70kDa ribosomal S6 kinases. Int J Biochem Cell Biol 43:47-59.
12. Flick DA and Gifford GE (1984) Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods 68:167-175. (Pubitemid 14133657)
13. Gallagher DJ and Kemeny N (2010) Metastatic colorectal cancer: from improved survival to potential cure. Oncology 78:237-248.
14. Gao J, Liu X, and Rigas B (2005) Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc Natl Acad Sci USA 102:17207-17212. (Pubitemid 41692708)
15. Giuliani F, De Vita F, Colucci G, and Pisconti S (2010) Maintenance therapy in colon cancer. Cancer Treat Rev 36:S42-S45.
16. Gupta AK, Cerniglia GJ, Mick R, McKenna WG, and Muschel RJ (2005) HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 65:8256-8265. (Pubitemid 41330590)
17. Hickok JR and Thomas DD (2010) Nitric oxide and cancer therapy: the emperor has NO clothes. Curr Pharm Des 16:381-391.
18. Kashfi K and Rigas B (2007) The mechanism of action of nitric oxide-donating aspirin. Biochem Biophys Res Commun 358:1096-1101. (Pubitemid 46829001)
19. Kleinman HK, McGarvey ML, Liotta LA, Robey PG, Tryggvason K, and Martin GR (1982) Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 21:6188-6193. (Pubitemid 13141622)
20. Labianca R and Merelli B (2010) Screening and diagnosis for colorectal cancer: present and future. Tumori 96:889-901.
21. Lebbé C, Blum L, Pellet C, Blanchard G, Vérola O, Morel P, Danne O, and Calvo F (1998) Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 12:F45-F49. (Pubitemid 28190688)
22. Maksimovic-Ivanic D, Mijatovic S, Harhaji L, Miljkovic D, Dabideen D, Fan Cheng K, Mangano K, Malaponte G, Al-Abed Y, Libra M, et al. (2008) Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5- dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo. Mol Cancer Ther 7:510-520. (Pubitemid 351482134)
23. Maksimovic-Ivanic D, Mijatovic S, Miljkovic D, Harhaji-Trajkovic L, Timotijevic G, Mojic M, Dabideen D, Cheng KF, McCubrey JA, Mangano K, et al. (2009) The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. Mol Cancer Ther 8:1169-1178.
24. Mijatovic S, Maksimovic-Ivanic D, Mojic M, Malaponte G, Libra M, Cardile V, Miljkovic D, Harhaji L, Dabideen D, Cheng KF, et al. (2008) Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide (GIT-27NO) induces p53 mediated apoptosis in human A375 melanoma cells. Nitric Oxide 19:177-183.
25. Mijatovic S, Maksimovic-Ivanic D, Mojic M, Timotijevic G, Miljkovic D, Mangano K, Donia M, Di Cataldo A, Al-Abed Y, Cheng KF, et al. (2011) Cytotoxic and immune-sensitizing properties of nitric oxide-modified saquinavir in iNOS-positive human melanoma cells. J Cell Physiol 226:1803-1812.
26. Mijatovic S, Maksimovic-Ivanic D, Timotijevic G, Miljkovic D, Donia M, Libra M, Coco M, McCubrey J, Al-Abed Y, Korac A, et al. (2010) Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. Free Radic Biol Med 48:1090-1099.
27. Mojic M, Mijatovic S, Maksimovic-Ivanic D, Dinic S, Grdovic N, Miljkovic D, Stosic-Grujicic S, Tumino S, Fagone P, Mangano K, et al. (2012) Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. Cell Cycle 11:1174-1182.
28. Niehues T, Horneff G, Megahed M, Schroten H, and Wahn V (1999) Complete regression of AIDS-related Kaposi's sarcoma in a child treated with highly active antiretroviral therapy. AIDS 13:1148-1149. (Pubitemid 29361413)
29. Rigas B and Williams JL (2008) NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide 19:199-204.
30. Rothweiler F, Michaelis M, Brauer P, Otte J, Weber K, Fehse B, Doerr HW, Wiese M, Kreuter J, Al-Abed Y, et al. (2010) Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia 12:1023-1030.
31. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, and Meade TW (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377:31-41.
32. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, and Meade TW (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741-1750.
33. Sahai E and Marshall CJ (2003) Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 5:711-719. (Pubitemid 36986778)
34. Schütt M, Zhou J, Meier M, and Klein HH (2004) Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 β cells. J Endocrinol 183:445-454. (Pubitemid 40057575)
35. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, et al. (2002) HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 8:225-232. (Pubitemid 34250099)
36. Sgadari C, Monini P, Barillari G, and Ensoli B (2003) Use of HIV protease inhibitors to block Kaposi's sarcoma and tumour growth. Lancet Oncol 4:537-547. (Pubitemid 38351710)
37. Singh S and Gupta AK (2011) Nitric oxide: role in tumour biology and iNOS/NO-based anticancer therapies. Cancer Chemother Pharmacol 67:1211-1224.
38. Stojanovic I, Cuzzocrea S, Mangano K, Mazzon E, Miljkovic D, Wang M, Donia M, Al Abed Y, Kim J, Nicoletti F, et al. (2007) In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin Immunol 123:311-323. (Pubitemid 46824126)
39. Stosic-Grujicic S, Cvetkovic I, Mangano K, Fresta M, Maksimovic-Ivanic D, Harhaji L, Popadic D, Momcilovic M, Miljkovic D, Kim J, et al. (2007) A potent immunomodulatory compound, (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. J Pharmacol Exp Ther 320:1038-1049. (Pubitemid 46294054)
40. Toschi E, Sgadari C, Malavasi L, Bacigalupo I, Chiozzini C, Carlei D, Compagnoni D, Bellino S, Bugarini R, Falchi M, et al. (2011) Human immunodeficiency virus protease inhibitors reduce the growth of human tumors via a proteasome-independent block of angiogenesis and matrix metalloproteinases. Int J Cancer 128:82-93.
41. Van Geelen CM, de Vries EG, and de Jong S (2004) Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 7:345-358. (Pubitemid 40341956)
42. Wolpin BM and Mayer RJ (2008) Systemic treatment of colorectal cancer. Gastroenterology 134:1296-1310.
43. Yeh RK, Chen J, Williams JL, Baluch M, Hundley TR, Rosenbaum RE, Kalala S, Traganos F, Benardini F, del Soldato P, et al. (2004) NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol 67:2197-2205. (Pubitemid 38639928)
44. Zhang Y, Yuan J, Zhang HY, Simayi D, Li PD, Wang YH, Li F, and Zhang WJ (2012) Natural resistance to apoptosis correlates with resistance to chemotherapy in colorectal cancer cells. Clin Exp Med 12:97-103.